{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"66.7"},{"groupId":"OG002","value":"42.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Percentage of eligible and evaluable patients with MRD \\< 0.01% among those who had successful MRD determination at the end of Block 2.","groups":[{"description":"Re-Induction Block 1 patients receive liposomal vincristine sulfate , Prednisone, pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1, 4, 8 \\& 11 of Block 1 and days 1, 4, \\& 8 of Block 2.","id":"OG000","title":"Pre-B ALL Relapse < 36 Mths From Dx (Chemotherapy) Age >21 Yrs"},{"description":"Re-Induction Block 1 patients receive liposomal vincristine sulfate , Prednisone, pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1, 4, 8 \\& 11 of Block 1 and days 1, 4, \\& 8 of Block 2.","id":"OG001","title":"Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs"},{"description":"Re-Induction Block 1 patients receive liposomal vincristine sulfate , Prednisone, pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1, 4, 8 \\& 11 of Block 1 and days 1, 4, \\& 8 of Block 2.","id":"OG002","title":"Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs"},{"description":"Re-Induction Block 1 patients receive liposomal vincristine sulfate , Prednisone, pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1, 4, 8 \\& 11 of Block 1 and days 1, 4, \\& 8 of Block 2.","id":"OG003","title":"T-cell ALL (Chemotherapy)"},{"description":"Re-Induction Block 1 patients receive liposomal vincristine sulfate , Prednisone, pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1, 4, 8 \\& 11 of Block 1 and days 1, 4, \\& 8 of Block 2.","id":"OG004","title":"T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"The MRD analysis is limited to eligible and evaluable pre-B ALL with age \\<= 21 years who relapsed \\< 36 months only (stratum 1 \\& 2) and have successful MRD determination at the end of Block 2per protocol section 9.3.3.","reportingStatus":"POSTED","timeFrame":"End of Block 2 (Day 36 of Block 2) of re-induction therapy","title":"Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}